NCT00527618View on ClinicalTrials.gov

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Genital HerpesHIV Infection
Interventions
DRUG

valacyclovir

valacyclovir 1000 mg orally twice daily for 12 weeks.

DRUG

acyclovir

acyclovir 400 mg orally twice daily for 12 weeks.

Trial Locations (1)

98122

University of Washington Virology Research Clinic, Seattle

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Washington

OTHER

NCT00527618 - Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV | Biotech Hunter | Biotech Hunter